Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Durvalumab|DRUG: Trastuzumab
Sponsor: Canadian Cancer Trials Group
Collaborators: AstraZeneca